Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14059490 | 0.99 | TBK1 (0.79) | TBK1IKBKE | |
| SCHEMBL14061449 | 0.91 | TBK1 (0.69) | TBK1IKBKE | |
| SCHEMBL14059709 | 0.90 | TBK1 (0.87) | TBK1IKBKE | |
| SCHEMBL15737675 | 0.90 | TBK1 (0.68) | TBK1IKBKE | |
| SCHEMBL18969742 | 0.89 | TBK1 (0.80) | TBK1IKBKE | |
| SCHEMBL14058915 | 0.89 | TBK1 (1.00) | TBK1IKBKE | |
| SCHEMBL14059077 | 0.88 | TBK1 (1.00) | TBK1IKBKE | |
| SCHEMBL14059234 | 0.87 | TBK1 (1.00) | TBK1IKBKE | |
| SCHEMBL14059034 | 0.87 | TBK1 (1.00) | TBK1IKBKE | |
| SCHEMBL14059220 | 0.83 | TBK1 (1.00) | TBK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714668-B9 | THIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-06-14 | — | — | EP | claimed |
| EP-2714668-B1 | THIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-01-18 | — | — | EP | claimed |
| WO-2012161879-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-11-29 | — | — | WO | claimed |
| EP-2714668-B9 | THIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-06-14 | — | — | EP | disclosed |
| EP-2714668-B9 | THIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-06-14 | — | — | EP | disclosed |
| EP-2714668-B1 | THIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-01-18 | — | — | EP | disclosed |
| EP-2714668-B1 | THIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-9249114-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| US-9249114-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| US-20140148457-A1 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148457-A1 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| WO-2012161879-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148457-A1 | Thiazole derivatives | TBK1, IRAK1, IRF3 | TBK1 1/4885IKBKE 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.